INCLIX F-100
ApprovedQuantitative point-of-care immunoassay platform approved as a Class II device by Health Canada.
FROM PUBLIC EVENTS · 2026-11-15
Global approvals · expansion Approved for its point-of-care platform under a Canadian partner's brand, it is starting overseas supply.
Roles often seen at this stageRegulatory affairs · Sales & marketing · Device R&D & support
An in-vitro diagnostics company making a point-of-care immunoassay platform and allergy tests, widening sales with overseas partners.
Quantitative point-of-care immunoassay platform approved as a Class II device by Health Canada.
Allergy test approved in Korea and seeking European certification.
Its point-of-care platform was approved by Health Canada.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.